p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research

Phosphorylated tau (p-Tau) biomarkers have become a cornerstone of Alzheimer’s disease research and diagnosis — but not all p-Tau species offer the same diagnostic or prognostic value. In this webinar, the featured speaker will explore the scientific rationale and clinical relevance of p-Tau 205 and 212, two emerging biomarkers showing promise for improving early detection and disease staging.

Through an in-depth discussion of the latest research, analytical validation data and potential clinical applications, this session will illuminate how p-Tau 205/212 may offer complementary insights to established markers like p-Tau 181 and 217 — and help move the field closer to scalable, blood-based Alzheimer’s diagnostics.

Whether working in biomarker discovery, translational research or clinical development, this webinar will offer actionable insights into the next wave of neurodegenerative disease biomarkers.

Register for this webinar to learn how p-Tau 205 and 212 may advance Alzheimer’s disease diagnosis and biomarker precision.

Speakers

Thomas K Karikari, PhD, Assistant Professor of Psychiatry, University of Pittsburgh

Dr. Thomas Karikari, PhD, is the Director of the Biofluid Biomarker Laboratory at the University of Pittsburgh, where he also leads the Mass Spectrometry and Single Molecule Array Biomarker Programs in the Department of Psychiatry. He heads the Fluid Biomarker Core of the NIA Alzheimer’s Program Project Grant. Internationally recognized, Dr. Karikari specializes in discovering, validating and implementing biofluid biomarkers for Alzheimer’s and related neurodegenerative diseases. His lab developed the first widely used plasma p-Tau 181 assay and immunoassays for p-Tau 212, p-Tau 217 and p-Tau 231, as well as a CNS-specific brain-derived Tau marker. The lab also created a streamlined method for quantifying plasma amyloid beta peptides via immunoprecipitation-mass spectrometry. These tools are widely applied in diagnostics and clinical trials. Dr. Karikari has extensive experience managing clinical labs and standardizing preanalytical procedures for biospecimen collection and analysis, with a focus on scalable protocols suitable for community-based and resource-limited settings.

Message Presenter

Wesley Straub, Vice President of Product Management, Quanterix

Wesley Straub obtained his BS in Chemistry magna cum laude from Boston University and a PhD from the University of California San Francisco. After working on the production, purification, and characterization of several biosimilars, recombinant blood factors, and novel biotherapeutics, he entered the life science technology with Forte Bio. Wesley has contributed to the development and launch of over 25 hardware, software, and reagent products across biolayer interferometry, capillary sequencing, qPCR, and Simoa technologies.

Message Presenter